DOK6 Antibody
产品详情
-
产品名称:Rabbit anti-Homo sapiens (Human) DOK6 Polyclonal antibody
-
Uniprot No.:Q6PKX4
-
基因名:DOK6
-
别名:DOK6 antibody; DOK5LDocking protein 6 antibody; Downstream of tyrosine kinase 6 antibody
-
宿主:Rabbit
-
反应种属:Human
-
免疫原:Recombinant Human Docking protein 6 protein (109-331AA)
-
免疫原种属:Homo sapiens (Human)
-
标记方式:Non-conjugated
本页面中的产品,DOK6 Antibody (CSB-PA007112LA01HU),的标记方式是Non-conjugated。对于DOK6 Antibody,我们还提供其他标记。见下表:
-
克隆类型:Polyclonal
-
抗体亚型:IgG
-
纯化方式:>95%, Protein G purified
-
浓度:It differs from different batches. Please contact us to confirm it.
-
保存缓冲液:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
产品提供形式:Liquid
-
应用范围:ELISA
-
Protocols:
-
储存条件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
货期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
相关产品
靶点详情
-
功能:DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK6 promotes Ret-mediated neurite growth. May have a role in brain development and/or maintenance.
-
基因功能参考文献:
- DOK-6 is involved in RET signaling with less influence when compared with DOK-1, DOK-4, and SHC. PMID: 20210798
- Dok-6 binds to the phosphorylated Ret Tyr(1062) residue resulting in phosphorylation of tyrosine residue(s) located within the unique C terminus of Dok-6 predominantly through a Src-dependent mechanism PMID: 15286081
-
蛋白家族:DOK family, Type B subfamily
-
组织特异性:Highly expressed in fetal and adult brain. Highly expressed in the cerebellum. Weak expression in kidney, spinal cord and testis.
-
数据库链接:
HGNC: 28301
OMIM: 611402
KEGG: hsa:220164
STRING: 9606.ENSP00000372160
UniGene: Hs.278285
Most popular with customers
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
-